|Bid||106.41 x 800|
|Ask||112.25 x 800|
|Day's Range||110.58 - 112.20|
|52 Week Range||82.82 - 122.16|
|Beta (5Y Monthly)||0.32|
|PE Ratio (TTM)||36.93|
|Forward Dividend & Yield||1.57 (1.48%)|
|Ex-Dividend Date||Mar 25, 2022|
|1y Target Est||130.93|
Camp Huronda, home of Diabetes Canada's camp for children and youth living with type 1 diabetes and one of nine camps established under the D-Camps banner, is opening its doors to youth, families, and staff for the first time in two years. Diabetes Canada's Camps (D-Camps) strive to foster lifelong connections and provide exceptional programming for kids living with type 1 diabetes in a medically supervised environment.
Bagsværd, Denmark, 20 June 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme initiat
Novo Nordisk (NVO) possesses solid growth attributes, which could help it handily outperform the market.